Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 131

Sort by

Sort Order Select

Journal Articles

Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Normann Steiner, Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Gabriele Zeck, David Nachbaur, Dominik Wolf, Nico Gagelmann, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 3571.

https://doi.org/10.1182/blood-2024-205849

Published: 2024

Journal Articles

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Blood (2024) 144 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2024-210920

Published: 2024

Journal Articles

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2024-211410

Published: 2024

Journal Articles

Reconstructing Skeletal Homeostasis through Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

Mathias Schäfersküpper, Alexander Simon, Felix N. Von Brackel, Maximilian M. Delsmann, Anke Baranowsky, Thorsten Schinke, Michael Amling, Tim Rolvien, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 4940.

https://doi.org/10.1182/blood-2024-210778

Published: 2024

Journal Articles

Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

Kristin Rathje, Kordelia Barbullushi, Nico Gagelmann, Anita Badbaran, Johanna Richter, Mathias Schäfersküpper, Franziska Elisabeth Marquard, Radwan Massoud, Sofia Oechsler, Evgeny Klyuchnikov, Ina Rudolph, Silke Heidenreich, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 3547.

https://doi.org/10.1182/blood-2024-207569

Published: 2024

Journal Articles

The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

Radwan Massoud, Margherita Ursi, Francesco Barbato, Francesco De Felice, Enrico Maffini, Marcello Roberto, Evgeny Klyuchnikov, Claudia Langebrake, Nico Gagelmann, Gabriele Zeck, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kroeger, Francesca Bonifazi

Blood (2024) 144 (Supplement 1): 7374.

https://doi.org/10.1182/blood-2024-211102

Published: 2024

Journal Articles

CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis

Blood (2024) 144 (Supplement 1): 2073.

https://doi.org/10.1182/blood-2024-205103

Published: 2024

Journal Articles

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Nico Gagelmann, Gabriela S. Hobbs, Edoardo Campodonico, Polona Novak, Vaneuza Funke, Vanderson Rocha, Nelson Hamerschlak, Thomas Schroeder, Christina Rautenberg, Linette Bosques, Raffaella Greco, Artur Schneider, Grzegorz Helbig, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2023-191300

Published: 2023

Journal Articles

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3494.

https://doi.org/10.1182/blood-2023-174368

Published: 2023

Journal Articles

Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

Nico Gagelmann, Marie Quarder, Anita Badbaran, Christine Wolschke, Kristin Rathje, Mathias Schäfersküpper, Ameya Shrinivas Kunte, Evgeny Klyuchnikov, Radwan Massoud, Johanna Richter, Dietlinde Janson, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 630.

https://doi.org/10.1182/blood-2023-191242

Published: 2023

Journal Articles

Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Petra Freiberger, Christine Wolschke, Francis A. Ayuk, Ulrike Bacher, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 1588.

https://doi.org/10.1182/blood-2023-188998

Published: 2023

Journal Articles

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Kristin Rathje, Nico Gagelmann, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie-Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2023-185991

Published: 2023

Journal Articles

Spectrum of ASXL1 Mutations Show Similar Impact on Outcomes in Patients with Myelofibrosis Undergoing Transplantation

Nico Gagelmann, Anita Badbaran, Christine Wolschke, Mathias Schäfersküpper, Dietlinde Janson, Francis A. Ayuk, Boris Fehse, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 1843.

https://doi.org/10.1182/blood-2023-191280

Published: 2023

Journal Articles

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 7509–7511.

https://doi.org/10.1182/blood-2022-169459

Published: 2022

Journal Articles

Impact of High-Risk Disease on Outcome after CAR-T Cell Therapy for Multiple Myeloma: A Meta-Analysis of 759 Patients

Nico Gagelmann, Francis A. Ayuk, Anita Badbaran, Carolina Berger, Boris Fehse, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 7241–7242.

https://doi.org/10.1182/blood-2022-170061

Published: 2022

Journal Articles

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Nico Gagelmann, Anita Badbaran, Rachel Beth Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Arnold Ganser, Christina Rautenberg, Bruno Cassinat, Felicitas R Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 828–829.

https://doi.org/10.1182/blood-2022-158900

Published: 2022

Journal Articles

Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Christine Wolschke, Raissa Adjallé, Dietlinde Janson, Carolina Berger, Evgeny Klyuchnikov, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2022) 140 (Supplement 1): 7672–7673.

https://doi.org/10.1182/blood-2022-170107

Published: 2022

Journal Articles

Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

Ameya Shrinivas Kunte, Nico Gagelmann, Anita Badbaran, Carolina Berger, Radwan Massoud, Evgeny Klyuchnikov, Christine Wolschke, Dietlinde Janson, Ulrike Fritsche-Friedland, Boris Fehse, Nicolaus Kroeger, Francis A. Ayuk

Blood (2022) 140 (Supplement 1): 7531–7532.

https://doi.org/10.1182/blood-2022-168667

Published: 2022

Journal Articles

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Blood (2022) 140 (4): 349–358.

https://doi.org/10.1182/blood.2021015209

Published: 2022

Includes: Supplemental data

Journal Articles

Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

Blood (2021) 138 (Supplement 1): 3903.

https://doi.org/10.1182/blood-2021-144748

Published: 2021

NARROW

Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Reconstructing Skeletal Homeostasis through Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Mutation Clearance of Driver Mutations after Transplantation for Myelofibrosis Predicts Outcome

Leukemic Stem Cells (LSCs) As Peri-Transplant MRD Assessment in AML Patients Undergoing Allogeneic Stem Cell Transplantation in CR

ATG/ATLG Improves GvHD-Free and Relapse-Free Survival in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

Spectrum of ASXL1 Mutations Show Similar Impact on Outcomes in Patients with Myelofibrosis Undergoing Transplantation

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Impact of High-Risk Disease on Outcome after CAR-T Cell Therapy for Multiple Myeloma: A Meta-Analysis of 759 Patients

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only